Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical stage programs in GI disorders and dyslipidemia. The Company discovered, developed and is commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

Type
Public
HQ
Cambridge, US
Size (employees)
674 (est)
Ironwood Pharmaceuticals is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Ironwood Pharmaceuticals

Peter Hecht

Peter Hecht

Co-Founder
Brian Cali

Brian Cali

Co-Founder and Vice President of Program Management

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St
Show all (1)
Report incorrect company information

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Financials

Ironwood Pharmaceuticals's revenue was reported to be $273.96 m in FY, 2016 which is a 83.2% increase from the previous period.
USD

Revenue (Q3, 2017)

86.8 m

Net income (Q3, 2017)

(32.3 m)

EBIT (Q3, 2017)

(19.4 m)

Market capitalization (18-Apr-2018)

2.6 b

Cash (30-Sep-2017)

162.6 m

EV

2.7 b
Ironwood Pharmaceuticals's current market capitalization is $2.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

22.9 m76.4 m149.6 m274 m

Revenue growth, %

234%96%83%

General and administrative expense

173.3 m

R&D expense

139.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

52.2 m65.1 m86.8 m

Cost of goods sold

2 m1.9 m10.5 m12 k8.2 m12 k12 k

General and administrative expense

30.3 m29.9 m29.3 m28.5 m30.3 m33 m30.4 m36.2 m36.9 m45 m55.6 m57.8 m61.8 m

R&D expense

23 m27.1 m22.1 m25.1 m26.6 m28.6 m25.8 m31.8 m31.7 m37.5 m33.7 m37.3 m37.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

75.5 m74.3 m261.3 m54 m

Accounts Receivable

513 k10 k2.9 m933 k

Inventories

6.2 m10.6 m6.3 m1.1 m

Current Assets

229.1 m289.7 m500.2 m380.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

144.5 m205.1 m95.4 m51.3 m63.7 m256.5 m248.1 m280.9 m277.3 m182.9 m133.3 m182.1 m162.6 m

Accounts Receivable

125 k13 k380 k862 k1.1 m2.6 m908 k1.3 m1.2 m1.2 m4 m4.3 m

Inventories

20.6 m23.4 m13 m13 m5 m1.5 m1.1 m479 k

Current Assets

275.8 m371.3 m325.8 m304.1 m263.9 m527 m505.8 m495.7 m386.1 m382.8 m357.9 m341.5 m314.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)

Depreciation and Amortization

11.7 m12.3 m11.6 m10.3 m

Inventories

(52 k)(3.9 m)2.6 m(3.1 m)

Accounts Payable

(11.7 m)1.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(61.8 m)(49.6 m)(60.4 m)(42 m)(33.2 m)(48 m)(47.4 m)(13.3 m)(21.7 m)(33.2 m)(52.5 m)

Inventories

13 m13 m5 m1.5 m

Accounts Payable

3.4 m6.1 m
USDY, 2017

EV/EBIT

-140.2 x

Revenue/Employee

128.8 k
Show all financial metrics
Report incorrect company information